Biotechnology company Protego Biopharma has raised $130 million to advance its first-in-class AL amyloidosis programme to clinical trial. The proceeds from the over-subscribed Series B financing round will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis. PROT-001 works by stabilising immunoglobulin light chains and preventing amyloid buildup, addressing disease at its root cause rather than simply managing symptoms. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!